Xbrane Biopharma AB is a leading science based biosimilar developer of cost effective medicines with high unmet medical need. Xbrane base its development on a patented high yield production platform and world-leading expertise. Xbrane has a portfolio targeting originator products with combined annual sales of €11billion. The leading product, Xlucane (ranibizumab biosimilar), is currently in Phase III with target to launch 2022. Xbrane’s headquarter is located in Solna, just outside of Stockholm. Xbrane is listed on Nasdaq Stockholm with the ticker XBRANE.
Location: Sweden, Stockholm
Employees: 51-200
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Beijer Ven... | beijervent... |
Mentions in press and media 9
| Date | Title | Description |
| 20.03.2025 | Alvotech Acquires Xbrane’s R&D Operations in Sweden | Alvotech (NASDAQ: ALVO), a Reykjavik, Iceland-based biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, acquired Xbrane’s R&D operations and the biosimilar candidate XB003. The... |
| 03.04.2023 | STADA and Xbrane launch ranibizumab to support patient access in Europe | Peter Goldschmidt, STADA CEO • Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane This European-made biosimilar, developed through STADA’s strategic partnership with Xbrane, will he... |
| 01.07.2021 | Xbrane Biopharma : has carried out a directed share issue raising gross proceeds of SEK 380 millions | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, ... |
| 28.06.2021 | Xbrane Biopharma : XlucaneTM meets the primary endpoint in the pivotal Phase III trial with XlucaneTM – regulatory submission in EU and US planned for second half of 2021 | Xbrane Biopharma AB (publ) ('Xbrane' or 'the Company') (Nasdaq Stockholm: XBRANE) today announces top-line results from the 6 months interim read-out in the pivotal Phase III equivalence trial with the Lucentis® biosimilar candidate Xlucane... |
| 13.11.2020 | Xbrane Biopharma : Interim report January – September 2020 | Interim report January - September 2020 Despite the impact from Covid-19, the last patient was recruited in November to the ongoing registration based phase III study, Xplore. Financial summary third quarter 2020 Revenue amounted to SEK 0.0... |
| 13.11.2020 | XBRANE BIOPHARMA AB (PUBL) Xbrane Biopharma : Interim report January – September 2020 | Interim report January - September 2020 Despite the impact from Covid-19, the last patient was recruited in November to the ongoing registration based phase III study, Xplore. Financial summary third quarter 2020 Revenue amounted to SEK 0.0... |
| 12.11.2020 | XBRANE BIOPHARMA AB (PUBL) Xbrane Biopharma : has completed a directed share issue of approximately SEK 200 million | The board of directors of the Company have, pursuant to the authorization granted by the extraordinary general meeting on 22 September 2020, resolved on the Directed Share Issue of 2,919,708 new shares at a subscription price of SEK 68.50 p... |
| 12.11.2020 | Xbrane Biopharma : has completed a directed share issue of approximately SEK 200 million | The board of directors of the Company have, pursuant to the authorization granted by the extraordinary general meeting on 22 September 2020, resolved on the Directed Share Issue of 2,919,708 new shares at a subscription price of SEK 68.50 p... |
| 15.10.2015 | Xbrane Acquires Primm Pharma | Xbrane, a Stockholm, Sweden-based biopharmaceutical company specialized in High Demand Complex Generics, acquired Primm Pharma, a Milan, Italy-based company specialized in the development and production of pharmaceutical formulations for sl... |